Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

61. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis

Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis Kwok CS, Nijjar RS, Loke YK CRD summary The authors concluded (...) that proton-pump inhibitors were associated with a reduction in adverse gastrointestinal events (particularly haemorrhages) in patients who were receiving dual antiplatelet therapy (clopidogrel and aspirin). Potential bias in the review process and reliance on lower quality study designs mean that the reliability of this conclusion is uncertain. Authors' objectives To evaluate the effects of proton-pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel. Searching PubMed, EMBASE

DARE.2012

62. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.

Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. OBJECTIVE: To examine the association between chronic use of proton pump inhibitors (PPIs) and risk of hip fracture. DESIGN: Prospective cohort study. SETTING: Nurses' Health Study, which originally recruited from the 11 most populous states in the US. PARTICIPANTS: 79,899 postmenopausal women enrolled in the Nurses' Health Study who provided data on the use of PPIs (...) and other risk factors biennially since 2000 and were followed up to 1 June 2008. MAIN OUTCOME MEASURE: Incident hip fracture RESULTS: During 565,786 person years of follow-up, we documented 893 incident hip fractures. The absolute risk of hip fracture among regular users of PPIs was 2.02 events per 1000 person years, compared with 1.51 events per 1000 person years among non-users. Compared with non-users, the risk of hip fracture among women who regularly used PPIs for at least two years was 35

BMJ2012 Full Text: Link to full Text with Trip Pro

64. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis

Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, Thota P, Sferra TJ, Hernandez AV CRD summary The authors concluded that proton pump inhibitors were associated (...) with a moderate increase in the risk of developing Clostridium difficile , but the observational nature of the evidence did not permit causality to be established. These conclusions reflect the evidence, but the uncertain causality and variation between studies mean that the actual risk of infection with proton pump inhibitors remains unclear. Authors' objectives To assess the association between proton pump inhibitor therapy and the risk of Clostridium difficile infection. Searching Five electronic databases

DARE.2012

65. Cohort study: Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events

Cohort study: Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events Article Text Prognosis

Evidence-Based Medicine (Requires free registration)2012

66. Randomised controlled trial: Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors

Randomised controlled trial: Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use (...) with gastro-oesophageal reflux disease who respond well to proton pump inhibitors Article Text Therapeutics Randomised controlled trial Laparoscopic antireflux surgery and esomeprazole similarly efficacious for symptoms in people with gastro-oesophageal reflux disease who respond well to proton pump inhibitors George Triadafilopoulos Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Galmiche JP , Hatlebakk J , Attwood S , et al . Laparoscopic antireflux surgery vs esomeprazole treatment

Evidence-Based Medicine (Requires free registration)2012

67. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel

A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel Chen M, Wei JF, Xu YN, Liu XJ, Huang DJ CRD summary The review noted that there was a discrepancy between the results of randomised controlled trials and observational studies when comparing clopidogrel plus proton pump inhibitor (...) with clopidogrel alone on cardiovascular and stroke outcomes; more research was required to adequately assess effects. Given substantial differences between the included studies and limitations in the evidence base, the authors' conclusions are appropriate. Authors' objectives To compare the effects of the combination of proton pump inhibitors and clopidogrel versus clopidogrel alone for antiplatelet treatment. Searching MEDLINE, EMBASE, The Cochrane Library, clinical trials registers, cardiology websites

DARE.2012

68. Proton pump inhibitors in long-term use: reports of hypomagnesaemia

Proton pump inhibitors in long-term use: reports of hypomagnesaemia Proton pump inhibitors in long-term use: reports of hypomagnesaemia Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Proton pump inhibitors in long-term use: reports of hypomagnesaemia From: Published: 20 April 2012 Therapeutic area: Healthcare professionals should consider measuring magnesium levels before starting PPI treatment and repeat measurements periodically during prolonged treatment (...) . Article date: April 2012 Proton pump inhibitors (PPIs) are a class of drugs for the treatment of duodenal and gastric ulcers, and are used in combination with antibacterials for the eradication of Helicobacter pylori. They are also used to treat gastroesophageal reflux disease, dyspepsia, and Zolligner-Ellison syndrome and for prevention and treatment of ulcers associated with the use of non-steroidal anti-inflammatory drugs. The class of PPIs includes esomeprazole (Nexium), lansoprazole (Zoton

MHRA Drug Safety Update2012

69. Proton pump inhibitors in long-term use: increased risk of fracture

Proton pump inhibitors in long-term use: increased risk of fracture Proton pump inhibitors in long-term use: increased risk of fracture Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Proton pump inhibitors in long-term use: increased risk of fracture From: Published: 20 April 2012 Therapeutic area: Recent epidemiological evidence of an increased risk of fracture with long-term use of proton pump inhibitors (PPIs). Article date: April 2012 Observational studies (...) on a risk of fracture associated with PPIs suggest there may be a modest increase in the risk of hip, wrist, or spine fracture, especially if PPIs are used in high doses and over long durations (>1 year). The increased risk was observed mainly in elderly patients, and it is possible that other risk factors contribute to the increase in risk. Two meta-analyses of published pharmacoepidemiology studies suggest the risk of fracture is increased by 10–40% above baseline. The primary studies

MHRA Drug Safety Update2012

70. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis

Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis Trikudanathan G, Israel J, Cappa J, O'Sullivan DM CRD summary This review (...) found a statistically significant association between acid suppressive therapy using proton pump inhibitors and the development of spontaneous bacterial peritonitis in patients with cirrhosis. Lack of information about the studies and their quality mean that the authors' conclusions should be interpreted with substantial caution and may not be reliable. Authors' objectives To determine the nature of the association between proton pump inhibitors and spontaneous bacterial peritonitis in patients

DARE.2011

71. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention

Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention Saini SD, Fendrick AM, Scheiman JM Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of proton-pump inhibitor (PPI) co-therapy to reduce dyspepsia in patients aged 50 years or older, receiving long-term, low-dose aspirin, for the secondary prevention of cardiovascular disease

NHS Economic Evaluation Database.2011

72. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial

A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial 21402616 2011 08 08 2011 10 13 2014 11 20 1468-3288 60 9 2011 Sep Gut Gut A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. 1182-8 10.1136/gut (...) .2010.235630 o evaluate the efficacy and tolerability of add-on treatment with lesogaberan (AZD3355), a novel reflux inhibitor, in patients with persistent gastro-oesophageal reflux disease (GORD) symptoms despite proton pump inhibitor (PPI) therapy. double-blind, placebo-controlled, randomised, parallel-group, multicentre phase IIA study was carried out in outpatient clinics. The study group comprised 244 adult patients with persistent GORD symptoms (heartburn and/or regurgitation) of at least mild

EvidenceUpdates2011

73. Proton pump inhibitor use and the antifracture efficacy of alendronate

Proton pump inhibitor use and the antifracture efficacy of alendronate 21321287 2011 06 14 2011 09 22 2013 11 21 1538-3679 171 11 2011 Jun 13 Archives of internal medicine Arch. Intern. Med. Proton pump inhibitor use and the antifracture efficacy of alendronate. 998-1004 10.1001/archinternmed.2011.20 Proton pump inhibitors (PPIs) are widely used in elderly patients and are frequently coadministered in users of oral bisphosphonates. Biologically, PPIs could affect the absorption of calcium (...) , vitamin B(12), and bisphosphonates and could affect the osteoclast proton pump, thus interacting with bisphosphonate antifracture efficacy. Moreover, PPIs themselves have been linked to osteoporotic fractures. Population-based, national register-based, open cohort study of 38,088 new alendronate sodium users with a mean duration of follow-up of 3.5 years. We related risk of hip fracture to recent pharmacy records of refill of prescriptions for alendronate. For hip fractures, there was statistically

EvidenceUpdates2011

74. Cost-utility of aspirin and proton pump inhibitors for primary prevention

Cost-utility of aspirin and proton pump inhibitors for primary prevention Cost-utility of aspirin and proton pump inhibitors for primary prevention Cost-utility of aspirin and proton pump inhibitors for primary prevention Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of aspirin with or without a proton-pump inhibitor (PPI) to prevent gastrointestinal bleeding, while preventing coronary heart disease. Adding a PPI to aspirin was not cost-effective for men with an average risk of bleeding, but was potentially cost-effective for men with an increased risk of bleeding. The cost-effectiveness methods were valid and key areas

NHS Economic Evaluation Database.2011

75. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis

The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis Chan WW, Chiou E, Obstein KL, Tignor AS, Whitlock TL CRD summary This review concluded that proton-pump inhibitor therapy in adults with asthma resulted in a small improvement in the morning peak expiratory flow rate (...) , but this was unlikely to be clinically meaningful. Despite some reporting limitations, the authors' conclusions broadly reflected the evidence presented and are likely to be reliable. Authors' objectives To evaluate the efficacy of proton-pump inhibitors in asthma control for adults with or without symptomatic gastro-oesophageal reflux disease. Searching MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched, without language restrictions, to January 2010; search terms were

DARE.2011

76. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention

Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention 21247527 2011 03 07 2011 06 03 2015 11 19 1879-1913 107 6 2011 Mar 15 The American journal of cardiology Am. J. Cardiol. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. 871-8 10.1016/j.amjcard.2010.10.073 The aim of the present study was to analyze the effect of drug exposure patterns of clopidogrel and proton pump inhibitors (...) (PPIs) on the clinical outcomes after percutaneous coronary intervention (PCI). Previous analyses predominantly included discharge medications and did not explore the effect of the drug exposure patterns. We analyzed all-cause death, nonfatal myocardial infarction, repeat revascularization, and major adverse cardiovascular events (MACE) in a cohort of 23,200 post-PCI patients (January 2003 to December 2008) using a multivariate adjusted Cox model and propensity-matched case-control analysis

EvidenceUpdates2011

77. Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention

Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention 21325111 2011 02 17 2011 04 04 2016 11 22 1538-3679 171 3 2011 Feb 14 Archives of internal medicine Arch. Intern. Med. Cost-utility of aspirin and proton pump inhibitors for primary prevention. 218-25 10.1001/archinternmed.2010.525 Aspirin reduces myocardial infarction but increases gastrointestinal tract (GI) bleeding. Proton pump inhibitors (PPIs) may reduce upper GI bleeding. We estimate the cost-utility of aspirin (...) treatment with or without a PPI for coronary heart disease (CHD) prevention among men at different risks for CHD and GI bleeding. We updated a Markov model to compare costs and outcomes of low-dose aspirin plus PPI (omeprazole, 20 mg/d), low-dose aspirin alone, or no treatment for CHD prevention. We performed lifetime analyses in men with different risks for cardiovascular events and GI bleeding. Aspirin reduced nonfatal myocardial infarction by 30%, increased total stroke by 6%, and increased GI

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

78. Systematic review: Proton pump inhibitors given before endoscopy for upper gastrointestinal bleeding do not improve survival, rebleeding or need for surgery

Systematic review: Proton pump inhibitors given before endoscopy for upper gastrointestinal bleeding do not improve survival, rebleeding or need for surgery Proton pump inhibitors given before endoscopy for upper gastrointestinal bleeding do not improve survival, rebleeding or need for surgery | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Proton pump inhibitors given before endoscopy for upper gastrointestinal bleeding do not improve survival, rebleeding or need for surgery Article Text Therapeutics Systematic review Proton pump inhibitors given before

Evidence-Based Medicine (Requires free registration)2011

79. Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness

Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness CADTH Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions Limited evidence showed that celecoxib versus non-COX-2 selective non-steroidal

Health Technology Assessment (HTA) Database.2011

80. Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials

Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials Proton pump inhibitors versus histamine-2-receptor (...) antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials Yang Z, Wu Q, Liu Z, Wu K, Fan D CRD summary The review concluded that proton pump inhibitors were superior to histamine-2-receptor antagonists for the prevention of delayed bleeding with no evidence of differences in the reduction of epigastric pain or ulcer healing after endoscopic mucosal resection or submucosal dissection. The review

DARE.2011